Core Viewpoint - The article discusses the evolution of investment strategies in the ITBT (Information Technology + Biotechnology) sector, highlighting the importance of belief and confidence in the industry and its founders during challenging times [6][35]. Group 1: Investment Journey - In 2022, the investment landscape for biotechnology was bleak, with negative news dominating the market [6]. - After a period of self-doubt, the successful IPO of Crystal Technology in June 2024 marked a turning point for the investment portfolio in the biotechnology sector [7]. - Five sources of capital have seen a collective explosion in their biotechnology investments, with over 7 significant overseas business development transactions announced in the last 12 months, totaling over 100 billion RMB [7]. Group 2: Organizational Evolution - The transition from individual efforts to a specialized team of PhDs in biotechnology reflects the organizational evolution of Five Sources Capital [8]. - The promotion of a young investor to partner status signifies the recognition of a complete growth cycle within the firm, navigating through various market phases [9][10]. - The article illustrates how a leading VC firm captures new opportunities and develops new capabilities through organizational evolution [11]. Group 3: Investment Philosophy - The investment approach emphasizes the importance of intuition and imagination over rigid frameworks, seeking individuals who can innovate and challenge existing norms [14]. - The firm aims to validate its investment methodology across unfamiliar fields, demonstrating its adaptability and generalized capabilities [15][16]. - The concept of "trial and error" is central to the investment process, allowing for hypothesis testing and validation in uncertain environments [18]. Group 4: Market Dynamics - The period from 2020 to 2021 was characterized by a bubble in the ITBT sector, leading to misjudgments about the actual progress of companies based on market enthusiasm [22][23]. - The subsequent market downturn in 2022 and 2023 resulted in significant challenges, with many previously successful companies struggling to secure funding [29][30]. - The article highlights the importance of distinguishing between genuine signals of progress and mere market hype, emphasizing the need for a deeper understanding of the industry [26][27]. Group 5: Future Outlook - The current stage of biotechnology investment is marked by the realization of substantial returns and the emergence of companies that can deliver high-quality assets [45]. - Five Sources Capital has adapted its strategy by building a specialized team to enhance its understanding of drug assets and improve investment decision-making [46]. - The firm focuses on long-term paradigm shifts rather than short-term trends, seeking companies with platform-level competitive advantages [49].

Core Viewpoint - The article discusses the evolution of investment capabilities in the VC sector, particularly focusing on the journey of Wuyuan Capital and its investment in the ITBT (Information Technology + Biotechnology) sector, highlighting the importance of belief and adaptability in navigating market fluctuations [2][3][4]. Group 1: Investment Journey and Market Dynamics - In 2022, Wuyuan Capital faced a challenging environment in the biopharmaceutical sector, leading to self-doubt among investors [3][4]. - By June 2024, Wuyuan Capital's portfolio saw significant success, with multiple companies going public and over five companies submitting IPO applications, alongside seven major overseas business development transactions totaling over 100 billion RMB in the last 12 months [4]. - The transition from a "single soldier operation" to a professional team with multiple PhDs reflects the growing importance of the biopharmaceutical sector alongside AI and hard technology [5]. Group 2: Learning from Mistakes and Market Realities - The period from 2020 to 2021 was characterized by a bubble in the ITBT sector, where the influx of capital led to inflated valuations, causing a misjudgment of actual industry progress [18][20]. - The subsequent market downturn in 2022-2023 resulted in significant losses for many companies, with Wuyuan Capital experiencing internal pressure as project funding dried up [23][24]. - Despite the challenges, Wuyuan Capital continued to invest in promising companies during the downturn, demonstrating a commitment to fundamental analysis rather than following market trends [33]. Group 3: Evolving Investment Strategies - The current stage of biopharmaceutical investment involves recognizing the potential of companies that have built competitive advantages, as seen with firms like Jingtai Technology and Yuanshi Peptide [22][35]. - Wuyuan Capital has adapted its investment strategy by recruiting specialized PhD teams to enhance its understanding of drug assets and to ensure a more robust evaluation process [37]. - The focus has shifted from traditional one-time transactions to platform-based business models that allow for collaboration with major pharmaceutical companies, thereby increasing operational efficiency and research capacity [38]. Group 4: Personal Growth and Industry Insights - The journey of a young partner at Wuyuan Capital illustrates the importance of resilience and the ability to maintain belief in the industry and its founders, even during tough times [29][41]. - The article emphasizes that the VC industry is not as glamorous as perceived, and it requires a mindset similar to entrepreneurship, where uncertainty and human factors play a significant role [43].